Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921540 | 1.00 | MDM2 (1.00) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL2054558 | 1.00 | MDM2 (1.00) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL2098298 | 1.00 | MDM2 (1.00) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL2054561 | 1.00 | MDM2 (1.00) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL2054556 | 1.00 | MDM2 (1.00) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL4400589 | 0.90 | MDM2 (0.82) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL23604990 | 0.85 | MDM2 (0.73) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL4391794 | 0.84 | MDM2 (0.72) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL4393778 | 0.84 | MDM2 (0.72) | MDM2MAPTTP53HTTFFAR1 | |
| SCHEMBL29921648 | 0.84 | MDM2 (0.72) | MDM2MAPTTP53HTTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163744-B2 | Tetrahydro-isoquinolin-1-ones for the treatment of cancer | NEXUSPHARMA, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163744-B2 | Tetrahydro-isoquinolin-1-ones for the treatment of cancer | NEXUSPHARMA, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163744-B2 | Tetrahydro-isoquinolin-1-ones for the treatment of cancer | NEXUSPHARMA, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090068144-A1 | TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER | NEXUSPHARMA INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090068144-A1 | TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER | NEXUSPHARMA INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090068144-A1 | TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER | NEXUSPHARMA INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068144-A1 | TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER | ING2, HMGB2, NOTCH2 | MDM2 9/4885MAPT 667/4885TP53 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.